DATA EXTRACTION AND SYNTHESIS One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality.
P rostate cancer is the most commonly diagnosed cancer in US men and the second leading cause of cancer death. 1 It has been estimated that in 2018, approximately 165 000 US men will be diagnosed with prostate cancer and 29 000 men will die of prostate cancer. 2 Prostate cancer incidence is 74% greater among African American than white men 1 and is also relatively greater in men with vs men without a family history of prostate cancer. 3 US prostate cancer incidence increased sharply with the dissemination of prostate-specific antigen (PSA)-based screening beginning in the late 1980s. 4 In 2012, the US Preventive Services
Task Force (USPSTF) recommended against PSA-based screening for prostate cancer, concluding that there was moderate certainty that the benefits of screening do not outweigh the harms (D recommendation). New evidence has since emerged from screening and treatment trials, and among US men prostate cancer is increasingly managed with active surveillance, in which treatment is deferred indefinitely unless evidence of progression is found during periodic physical examination, PSA-based testing, or repeat biopsy. This systematic review of screening and treatment benefits and harms and whether prebiopsy risk calculators can reliably detect higher-risk prostate cancers, along with a review of decision modeling studies, 5 was conducted to inform the USPSTF in its update of the 2012 recommendation regarding PSA-based screening for prostate cancer.
Methods

Scope of Review
This review addressed 5 key questions (KQs) ( Figure 1 ) encompassing the benefits and harms of PSA screening (KQ1 and KQ2), benefits and harms of treatments for localized prostate cancer (KQ3 and KQ4), and the utility of prebiopsy risk calculators to identify men with higher-risk prostate cancers (KQ5). Results addressing primary key questions are summarized here, while results for subquestions 2a, 3a, 4a, 4b, and 5a, as well as additional methodological details regarding search strategies, study inclusion criteria, quality assessment, excluded studies, and data analyses, are publicly available at https://www.uspreventiveservicestaskforce.org/Page/Document /UpdateSummaryFinal/prostate-cancer-screening1.
Data Sources and Searches
MEDLINE, PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were searched to locate studies informing the key questions (eMethods in the Supplement) that were published since the end of the search periods for the 2011 USPSTF reviews 7, 8 (July 1, 2011, through July 15, 2017) . Database searches were supplemented with expert suggestions and by reviewing reference lists from relevant systematic reviews and prior USPSTF reports. KQ5, on prebiopsy risk calculators, was new to this review; a preliminary search revealed that the earliest article in this field was published in 2006, so databases were searched from January 1, 2006, through October 6, 2016, for KQ5. Since October 2016, ongoing surveillance continued through article alerts and targeted searches of high-impact journals to identify studies published that could affect the conclusions or the related USPSTF recommendation. The last surveillance search was conducted in February 2018; during ongoing surveillance, we identified extended follow-up from a treatment trial, 9 2 cohort studies reporting longitudinal treatment outcomes, 10,11 and 3 studies of multivariable risk calculators. [12] [13] [14] We also included a recently published large screening trial. 15 
Study Selection
For KQ1, randomized clinical trials (RCTs) of asymptomatic men undergoing PSA screening vs no screening were included that assessed cancer incidence, prostate cancer-related morbidity, prostate cancer-specific mortality, or all-cause mortality. For KQ2, RCTs and cohort studies of asymptomatic men undergoing PSA screening or prostate biopsy after abnormal screening results were included that assessed the frequency of false-positive PSA screening, physical or psychological harms of screening or biopsy, or health-related quality of life. As has been performed for breast and lung cancer screening, [16] [17] [18] [19] extra-incidence data from trials were used to estimate the percentage of men diagnosed with cancer in the screening groups who were overdiagnosed. In the absence of overdiagnosis, the number of cases in the control group of a screening trial would be expected to eventually catch up with the number of cases diagnosed in the screening group; therefore, an excess of cases in the screening group with extended follow-up implies overdiagnosis. For KQ3 and KQ4, RCTs and comparative cohort studies of men with localized prostate cancer (stages T1-T2) were included that reported prostate cancer-specific morbidity or mortality, allcause mortality (KQ3), or physical or psychological harms of treatment, including adverse quality-of-life effects (KQ4). Studies were required to compare outcomes among men receiving active treatments (including radical prostatectomy, radiation therapy, androgen deprivation therapy, cryotherapy, or high-intensity focused ultrasound) and men receiving conservative management (ie, watchful waiting, active surveillance, observation, or no treatment). Because few studies were found for treatments other than radical prostatectomy and radiation therapy, only findings for radical prostatectomy and radiation therapy are summarized in this article; evidence on other treatment modalities is reviewed in the full evidence report. For KQ4 (treatment harms), uncontrolled observational studies with sample sizes of at least 100 men were also included.
For KQ5, external validation studies of multivariable risk calculators were included if they predicted the presence of "significant" prostate cancer using PSA testing in addition to patient variables routinely available before prostate biopsy (eg, patient characteristics, rectal examination results, PSA level). Significant prostate cancers were defined as either high grade (Gleason score Ն7) or clinical stage T2b or higher. Studies of novel serum biomarkers or imaging studies were excluded because results from these studies would not be routinely available before biopsy in most urology practices.
Data Extraction and Quality Assessment
Two reviewers independently appraised the quality of included articles using predefined criteria, 6, [20] [21] [22] [23] with disagreements resolved by consensus or consultation with a third investigator. One reviewer extracted study-level data into standardized evidence tables; a second checked data accuracy. Included studies were limited to those published in English and were rated as fair or good quality using USPSTF quality rating standards (eTable 1 in the Supplement). Poor-quality studies contained a fatal flaw or multiple significant limitations that could invalidate the results. Three poorquality RCTs of screening PSA were excluded. [24] [25] [26] Limitations of these studies included inadequate statistical power, 24-26 faulty analysis, 25 and potentially biased outcomes assessment.
24-26
Data Synthesis and Analysis
For each key question, the study designs, population characteristics, screening and treatment details, and overall results were summarized using descriptive statistics. Pooled meta-analyses were not performed for outcomes of screening effectiveness (KQ1), screening harms (KQ2), or treatment effectiveness (KQ3), because data on these outcomes derived from few studies with variable populations and interventions. For KQ4, random-effects meta-analyses were performed using the method of DerSimonian and Laird to estimate pooled relative risks (RRs) of urinary incontinence (ie, daily use of a pad or worse) and erectile dysfunction (ie, erections insufficient for intercourse) among patients receiving radical prostatectomy or radiation therapy vs conservative management. Statistical heterogeneity across studies was estimated using the I 2 statistic. Meta-analyses were performed using Stata version 14.2 (StataCorp). Pooled RRs were used to estimate the number of patients needed to be treated for 1 patient to be harmed (number needed to harm); in these calculations, the absolute risk of the harm in actively treated patients was estimated as In the PLCO trial, 76 683 US men aged 55 to 74 years were recruited from 1993 to 2001 and randomized to either annual PSA screening for 6 years or usual care. When men had PSA levels of 4.0 ng/mL or greater, they and their clinicians were informed; community physicians coordinated diagnostic evaluations and treatments. The PLCO trial has been characterized as comparing the effectiveness of organized vs opportunistic screening, 40 because during the screening phase of the trial, approximately 46% of control group participants received routine screening PSA testing from community physicians during each year, compared with approximately 85% of men in the screening group. 41 PSA testing was also common in both trial groups during the 7 years after the screening phase. emphasize outcomes among men in the "core" age group of 55 to 69 years at randomization.
f The Belgium site initially used a PSA threshold of 10.0 ng/mL and a screening interval of 7 years but transitioned to a threshold of 4.0 ng/mL and a 4-year interval by the end of the study.
g ERSPC-Goteborg reported longest (rather than median) follow-up, which was 14.0 years for incidence and all-cause mortality and 18.0 years for prostate cancer mortality.
h ERSPC-Finland reported hazard ratio rather than relative risk. Harms of Screening Key Question 2. What are the harms of PSA-based screening for prostate cancer and diagnostic follow-up? Evidence on the harms of PSA screening and diagnostic follow-up derives from the PLCO, CAP, and ERSPC trials (n = 647 906), as well as 2 good-quality and 3 fair-quality cohort studies (n = 297 971). 15 ,27,29,30,45-55
False-Positive Testing and Diagnostic Biopsies
Among men who underwent at least 1 PSA screen during the initial 4 (of 6) PLCO screening rounds (n = 32 576), 10.4% received at least 1 false-positive PSA screening result, 56 compared with 17.8%
of men who were screened at least once within 5 ERSPC centers (n = 61 604). 50 Across all PLCO screening rounds, 12.6% of men randomized to screening underwent 1 or more biopsies, resulting in a total of 6295 biopsies (16.4 biopsies per 100 men randomized to screening). Within ERSPC, the rate of biopsies among men randomized to screening was higher (27.7 biopsies per 100 men). Of biopsies performed in the 3 trials, 67.7%, 75.8%, and 60.6% did not result in a prostate cancer diagnosis in the PLCO, ERSPC, and CAP trials, respectively.
15,30,52
Among men undergoing a single round of PSA screening within the Veterans Affairs health system (n = 295 645), 8.5% had a PSA level of 4 ng/mL or greater; of these, 32.9% underwent followed by normal biopsy results had increased prostate cancerspecific worry up to 1 year after biopsy but no increase in depression or trait anxiety.
Overdiagnosis
The percentage of detected cancers that were overdiagnosed was estimated using the excess incidence method applied to screening trials data (eTable 2 in the Supplement). 18 When overdiagnosis was estimated as a percentage of all prostate cancers diagnosed, 16.4% of prostate cancers were overdiagnosed in the PLCO trial, 33.2% in the ERSPC trial, and 40.7% in the CAP trial. When estimated as a percentage of cancers detected by screening during the 2 trials reporting such data, 20.7% of cancers were overdiagnosed in the PLCO trial and 50.4% in the ERSPC trial. The extent of overdiagnosis varied across ERSPC sites, with higher rates of overdiagnosis occurring at 2 sites that also reported statistically significantly reduced prostate cancer mortality with screening.
33,35
Benefits of Early Detection Key Question 3. Is there evidence that various treatment approaches for early-stage or screen-detected prostate cancer reduce morbidity and mortality? Three RCTs (n = 2524) 9,58,59 and 7 cohort studies (n = 64 965) 11,60-65 assessed morbidity and mortality with radical prostatectomy compared with conservative management, and 1 RCT (n = 1090) 58 and 7 cohort studies (n = 60 585) 11,60-65 compared radiation therapy with conservative management ( Table 2) . Conservative management in these studies consisted of observation without treatment, active surveillance, watchful waiting, or a combination of these approaches. Comparative studies of benefits and harms associated with other treatment modalities are summarized in the full evidence report. The ProtecT trial randomized men with localized, screendetected prostate cancer to radical prostatectomy, radiation therapy (with neoadjuvant androgen deprivation therapy), or active surveillance (consisting of periodic PSA monitoring without surveillance biopsy).
58 During a median follow-up of 10 years, 54.8% of men randomized to active surveillance received treatment, mostly commonly radical prostatectomy; prostate cancer survival was approximately 99% in each group, with no statistically significant differences in prostate cancer mortality or all-cause mortality. In the ProtecT trial, incidence of metastatic disease among men randomized to active surveillance (6.3 cases per 1000 personyears) was higher than among men randomized to radical prostatectomy or radiation therapy (2.4 and 3.0 cases per 1000 personyears; P = .004 for overall difference across groups). Approximately 27 (95% CI, 16-77) and 32 (95% CI, 18-143) men with screendetected localized cancer would need to be treated with radical prostatectomy and radiation therapy (rather than active surveillance), respectively, to prevent 1 man from progressing to metastatic disease within 10 years. In both the SPCG-4 and PIVOT trials, radical prostatectomy was also associated with reduced progression to metastatic or systemic disease (SPCG-4: RR, 0.57 [95% CI, 0.44-0.75]; PIVOT: HR, 0.64 [95% CI, 0.42-0.97]). 9, 59 Compared with conservative management, radical prostatectomy and radiation therapy were associated with reduced prostate cancer mortality and all-cause mortality in several fair-to goodquality cohort studies (Table 2) .
60-65 However, cohort study estimates often diverged from RCT estimates, and cohort studies of treatments may be susceptible to residual confounding.
Harms of Treatment
Key Question 4. What are the harms of the various treatment approaches for early-stage or screen-detected prostate cancer? Three RCTs (n = 2524) 66-68 and 11 cohort studies (n = 8809) 10,11,69-78 compared harms among men treated with radical prostatectomy compared with conservative management, and 6 uncontrolled studies of surgical harms related to radical prostatectomy were included. [79] [80] [81] [82] [83] [84] Two RCTs (n = 1198) 66,67,85 and 12 cohort studies (n = 4762) 10,11,69-78,86 compared harms among men treated with radiation therapy compared with conservative management, and 1 uncontrolled observational study of radiation therapy was included (n = 3180).
87
Both urinary incontinence and erectile dysfunction occurred more commonly in men who underwent radical prostatectomy than in men receiving conservative management ( Figure 3 and Figure 4 ). Pooled relative risks of incontinence with radical prostatectomy were 2.27 (95% CI, 1.82-2.84; I 2 = 0.0%) in 3 RCTs and 2.75 (95% CI, 1.78-4.23; I 2 = 63.0%) in 6 cohort studies. Based on risk differences estimated from RCT data, 7.9 men (95% CI, 5.4-12.2) would need to be treated with radical prostatectomy rather than conservative management for 1 additional man to develop incontinence.
In pooled meta-analyses of the 3 RCTs, there was marked statistical heterogeneity in the relative risk of erectile dysfunction with radical prostatectomy (I 2 = 87.5%), which was attributable to a disparate outcome from the ProtecT trial, in which many men randomized to active surveillance received radical treatments during the comparatively long 6 years of median follow-up for harms ( Figure 4) . 66 After excluding the ProtecT trial from the RCT meta-analysis, the pooled relative risk of erectile dysfunction associated with radical prostatectomy vs conservative management was 1.82 (95% CI, 1.62-2.04; I 2 = 0.0%). Based on estimated risk differences from this pooled analysis, 2.7 men (95% CI, 2.2-3.6) need to be treated with radical prostatectomy rather than conservative management for 1 additional man to develop erectile dysfunction. Clinical
In 5 longitudinal studies, [9] [10] [11] 66 ,77 mean urinary and sexual function scores decreased to a nadir in the initial year after radical prostatectomy with some longer-term improvement, although urinary and sexual function typically remained statistically significantly lower than baseline up to 6 years after the procedure. Data on surgical complications and perioperative mortality associated with radical prostatectomy are summarized in eTable 3 in the Supplement. In a cohort of US men undergoing radical prostatectomy, 1.7% experienced major medical complications (most commonly cardiac or pulmonary) and 5.3% experienced major surgical complications (requiring reintervention) within 30 days of surgery.
82 Across 2 trials and 6 cohort studies, the median perioperative mortality with radical prostatectomy was 0.29% (range, 0.0%-0.52%). There was marked variability across 8 studies comparing incidence of urinary incontinence with radiation and conservative management, so these were not meta-analyzed ( Figure 5 ). In the ProtecT trial, the prevalence of erectile dysfunction at 6 years of median follow-up was similar among men randomized to radiation therapy vs active surveillance (39.8% vs 36.2%; RR, 0.91 [95% CI, 0.77-1.08]), likely attributable to the substantial crossover to radical treatment of men randomized to active surveillance. 66 In contrast, in 8 cohort studies, the prevalence of erectile dysfunction was more common in men treated with radiation therapy compared with men receiving conservative management (pooled RR, 1.31 [95% CI, 1.20-1.42]; I 2 = 22.1%) ( Figure 6) . 10, 11, 69, 73, [75] [76] [77] 86 Based on the cohort data, 6.9 men (95% CI, 5.1-10.7) would need to be treated with radiation therapy rather than conservative management for 1 additional man to develop erectile dysfunction. Although 2 US studies observed longitudinal improvement in adverse effects of radiation therapy on sexual function, 10, 11 initial decrements in sexual function associated with radiation therapy persisted throughout a 3-year follow-up period in an Australian cohort.
77
In the ProtecT trial, 10.4% of men randomized to radiation therapy experienced bothersome bowel symptoms (eg, loose stools, fecal incontinence) at 6-month follow-up, which tended to diminish during the 6-year follow-up. 66 Two US cohort studies suggest a similar pattern, 10, 11 in contrast to an Australian cohort study in which adverse bowel effects of radiation therapy persisted during 3 years of follow-up.
In 3 trials comparing radical prostatectomy with conservative management, 9 Table 3 summarizes the evidence contained in this review. Direct evidence from 3 fair-quality trials demonstrates that PSA screening increases prostate cancer detection, especially of localized, less aggressive cancers, 30,39 and evidence from 4 ERSPC sites suggests that screening can reduce the long-term incidence of metastatic disease. 43 While the PLCO and CAP trials found no association between randomization to screening invitation and reduced prostate cancer mortality, the overall ERSPC trial found a relative risk of 0.79 for prostate cancer mortality with screening. 30 Differences in trial outcomes may have been attributable to greater baseline exposure to PSA testing and contamination in the PLCO trial, low adherence to invitation to a single PSA screen in the CAP trial, and higher adherence to screening and biopsy in the ERSPC trial. A recent analysis of individual patient data from both the PLCO and the ERSPC trials suggests that results from both trials are consistent with approximately 25% to 30% relative reduction in the risk of prostate cancer death with screening vs no screening after accounting for differences in baseline risk, screening adherence, contamination, and the intensity of postscreening diagnostic evaluation. 100 In the ERSPC trial, 27 men needed to be diagnosed (and potentially treated) to prevent 1 prostate cancer death, underscoring the potential for overdiagnosis and overtreatment with PSA screening. 30 Evidence is limited on the benefit of screening among men older than 70 years or the differential benefits among African American men or men with a family history of prostate cancer. Trial data demonstrate that abnormal PSA screening test results are common and that most men referred for biopsy after abnormal screening results will not have prostate cancer.
15,30,52
Biopsy harms include pain, bleeding, and infection, 53 but perhaps the most serious harm of prostate cancer screening is overdiagnosis, because overdiagnosis burdens men with the potential harms of diagnosis and treatment without improving life expectancy or quality of life. It was estimated that 16.4% to 50.4% of prostate cancers were overdiagnosed during the 3 trials, consistent with estimates based on ecological or modeling studies. 4, [101] [102] [103] [104] This review assessed both the immediate harms of screening as well as the consequent adverse effects of prostate cancer treatments. Most men undergoing radical prostatectomy will experience long-term sexual difficulties and approximately 17% will experience urinary difficulties, while approximately 36% of men receiving radiation therapy experience erectile problems and many will experience adverse bowel symptoms. 66 Nevertheless, compared with conservative management, active treatments for localized prostate cancer did not clearly compromise overall quality of life or global physical or mental health status, despite adverse sexual, urinary, and bowel effects. The ProtecT trial found similarly high prostate cancer survival among men with screen-detected, early-stage prostate cancer randomized to radical prostatectomy, radiation therapy, or active surveillance. Of men assigned to active surveillance, 45.2% remained under surveillance without receiving active treatment during the 10-year follow-up period, although an increase in the incidence of metastatic disease was observed in the active surveillance group (approximately 6% with active surveillance vs 2 to 3% with active treatment). In contrast to the ProtecT active surveillance protocol Radiation therapy associated with significantly reduced risk of progression to metastatic disease (3.0 vs 6.3 per 1000 person-years with radiation therapy and conservative management, respectively).
Only 1 trial (ProtecT) assessed the effectiveness of radiation therapy and was not powered to detect differences in all-cause mortality.
Only the ProtecT trial assessed effect of radiation therapy on metastatic disease.
Cohort studies vulnerable to confounding by unmeasured patient characteristics. Mortality results from other cohorts were mixed.
Small number of cohort studies available.
Potential confounding by indication in cohort studies of treatment effectiveness.
Potential bias in study estimates may limit applicability to US clinical practice. Pooled RR of erectile dysfunction, 1.6 (95% CI, 1.2-2.1;
No adverse effect of radical prostatectomy on physical or mental health status, anxiety, or depression relative to conservative management.
Inclusion of ProtecT in meta-analysis of erectile dysfunction may have increased heterogeneity because of (1) relatively long 6-y follow-up; and (2) crossover of >50% of men from conservative management to active treatment.
Studies had varying outcome definitions, inconsistent timing of follow-up measurements.
Many studies included predominately retropubic rather than robot-assisted radical prostatectomies.
Likely generalizable to US clinical practice.
Fair to good Cohort 11 (8809) Pooled RR of urinary incontinence with radical prostatectomy vs conservative management, 2.75 in 6 cohorts (95% CI, 1.78-4.23; I 2 = 63.0%).
Pooled RR of erectile dysfunction, 1.49 in 7 cohorts (95% CI, 1.34-1.65; I 2 = 59.2%).
Radical prostatectomy not associated with decrement in generic measures of quality of life vs conservative management.
RCT or uncontrolled observational 2 RCTs and 6 cohorts (150 001)
Median perioperative mortality after radical prostatectomy, 0.29% (range across 8 studies, including cohort studies and RCTs, 0.0% to 0.52%).
Thromboembolic or cardiovascular complications of radical prostatectomy ranged from 0.4%-9.0%.
Surgical complications required reintervention in ≈5% (US cohort). In ProtecT, radiation therapy not associated with erectile dysfunction vs active surveillance (RR, 0.9 [95% CI, 0.8-1.1]).
Bowel dysfunction more common with radiation therapy than conservative management in both trials.
No adverse effect of radiation therapy on physical or mental health status, anxiety, or depression, compared with conservative management (1 trial).
54.8% of men in ProtecT who were randomized to conservative management crossed over to active treatment, which may have increased rate of adverse effects in conservative management group.
Most studies of external-beam radiation therapy; relatively few studies of brachytherapy.
Fair to good Cohort 12 (4762) Marked variability across studies in estimates of risk of urinary incontinence with radiation therapy vs conservative management.
Pooled RR of erectile dysfunction with radiation therapy vs conservative management, 1.31 in 8 cohorts (95% CI, 1.20-1.42; I 2 = 22.1%).
Bowel dysfunction more common with radiation therapy vs conservative management (5 cohorts).
Radiation therapy not associated with decrement in generic measures of quality of life vs conservative management.
Androgen deprivation therapy
Cohort 3 (4662) Increased risk of erectile dysfunction with ADT (RR, range in RR, 1.6-2.9).
Worse function across several SF-36 domains (eg, physical function, vitality, emotional role).
Few studies; small sample sizes; varying outcome definitions; inconsistent timing of follow-up measurements.
Fair
High-intensity focused ultrasound Uncontrolled observational 7 (2239) Grade 2 urinary incontinence (ie, leaking with mild activity) or worse ranged from 0.0%-7.3%.
Among men with baseline potency, 37.3%-52.7% had erectile dysfunction after treatment (3 studies).
No studies compared HIFU with conservative management; only 1 study had a sample size exceeding 1000 men.
Likely generalizable to US clinical practice. Calibration and decision curve analyses mixed for each calculator.
Most cohorts included many symptomatic men in addition to men referred for biopsy after abnormal PSA screening result.
ERSPC calculator derived with prostate volume determined by ultrasound rather than digital rectal examination.
No RCTs of calculator use.
Results may not generalize to men referred for biopsy after abnormal PSA screening result.
Unclear how risk information from calculators would influence biopsy decisions by actual physicians and patients.
Effects on long-term prostate cancer outcomes unknown. that consisted of periodic PSA monitoring, many active surveillance protocols include surveillance biopsy or imaging, which might reduce metastatic disease risk, albeit with added harms associated with repeated biopsy. In contemporary case series, prostate cancerspecific survival estimates for patients receiving active surveillance have been as high as 99% at 10 years of follow-up, although since relatively few men in these series have had extended followup, uncertainty remains about long-term outcomes.
105
This review demonstrates that prebiopsy risk calculators can discriminate between men with and without high-risk cancer better than PSA screening alone, but net clinical benefit of routine calculator use in biopsy decisions is not established by existing evidence. Diagnostic or surveillance strategies based on serum or urine tests or multiparametric magnetic resonance imaging are under study, and some have been recommended by the National Comprehensive Cancer Network. 106 Further research is needed to elucidate whether the use of adjunctive tests can improve the balance of benefits and harms of PSA-based prostate cancer screening in community settings. Because the lead time for prostate cancer may be very long, current screening trials (with <15 years of median follow-up) might underestimate mortality benefits. Limited follow-up duration from trials may also exaggerate estimates of overdiagnosis based on extra incidence, although estimates based on longer-term follow-up may be influenced by posttrial PSA testing. In the PLCO trial, contamination among control group participants would be expected to bias trial results toward the null. The ERSPC trial, in contrast, was limited by unexplained stage-adjusted differences in prostate cancer treatments by study group that may have biased results in favor of screening.
107 There was also variation across ERSPC sites in recruitment methods, screening intervals, use of ancillary testing, and PSA thresholds for biopsy referral. The CAP trial was limited by the low adherence of intervention participants to the invitation to a single PSA screen. Across all studies, relatively few men older than 70 years were enrolled, and there is limited evidence about the differential benefits or harms of screening for men at higher risk. Of 4 randomized trials comparing the effectiveness and harms of treatments for localized prostate cancer, only the ProtecT trial exclusively enrolled men with screen-detected cancer, and prostate cancer-specific and all-cause mortality were extremely low in that study. 58 
